Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Up 7.8%

Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) shares rose 7.8% during mid-day trading on Thursday . The stock traded as high as $1.66 and last traded at $1.65. Approximately 401,392 shares changed hands during mid-day trading, an increase of 6% from the average daily volume of 378,469 shares. The stock had previously closed at $1.53.

EYPT has been the subject of several recent research reports. HC Wainwright reiterated a “buy” rating and issued a $4.50 price objective on shares of Eyepoint Pharmaceuticals in a research note on Thursday, May 9th. Zacks Investment Research upgraded Eyepoint Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, April 30th. Finally, ValuEngine cut Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, March 21st.

The business has a 50 day moving average of $1.64. The company has a debt-to-equity ratio of 1.77, a current ratio of 1.96 and a quick ratio of 1.93.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last released its earnings results on Wednesday, May 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.03). Eyepoint Pharmaceuticals had a negative net margin of 1,739.81% and a negative return on equity of 195.83%. The company had revenue of $2.01 million during the quarter, compared to analyst estimates of $3.70 million. As a group, analysts forecast that Eyepoint Pharmaceuticals Inc will post -0.4 earnings per share for the current fiscal year.

In related news, Director John B. Landis acquired 40,000 shares of Eyepoint Pharmaceuticals stock in a transaction dated Monday, May 13th. The shares were acquired at an average cost of $1.74 per share, for a total transaction of $69,600.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 18.91% of the stock is currently owned by insiders.

Large investors have recently made changes to their positions in the business. Arcus Capital Partners LLC acquired a new stake in Eyepoint Pharmaceuticals during the first quarter worth about $45,000. Bank of New York Mellon Corp increased its stake in Eyepoint Pharmaceuticals by 78.5% during the fourth quarter. Bank of New York Mellon Corp now owns 51,501 shares of the company’s stock worth $97,000 after acquiring an additional 22,645 shares during the last quarter. Tibra Equities Europe Ltd acquired a new stake in Eyepoint Pharmaceuticals during the first quarter worth about $202,000. Northern Trust Corp increased its stake in Eyepoint Pharmaceuticals by 10.8% during the fourth quarter. Northern Trust Corp now owns 113,544 shares of the company’s stock worth $215,000 after acquiring an additional 11,064 shares during the last quarter. Finally, Laurion Capital Management LP increased its stake in Eyepoint Pharmaceuticals by 152.5% during the first quarter. Laurion Capital Management LP now owns 188,600 shares of the company’s stock worth $338,000 after acquiring an additional 113,900 shares during the last quarter. Institutional investors own 58.29% of the company’s stock.

Eyepoint Pharmaceuticals Company Profile (NASDAQ:EYPT)

EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. It provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis (NIPU) that is in the Phase III clinical trials; and Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis.

See Also: What is the Stochastic Momentum Index (SMI)?

Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.